Discover
CAPR
Capricor Therapeutics, Inc.
23.07
2 x 17.28
2 x 29.55
bid
ask
-
1.01
4.19%
2 @ 04:23 AM
23.50 +0.43 (1.85%)
| Ytd | -20.06% | |
| 1y | 137.84% |
23.04
day range
24.25
4.30
52 week range
40.37
| Open | 24.05 | Prev Close | 24.08 | Low | 23.04 | High | 24.25 | Mkt Cap | 1.34B |
| Vol | 1.78M | Avg Vol | 1.15M | EPS | -2.32 | P/E | N/A | Forward P/E | -35.92 |
| Beta | 0.37 | Short Ratio | 13.95 | Inst. Own | 59.72% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 29.50 | 200-d Avg | 22.21 | 1yr Est | 53.60 |
CAPR News
benzinga.com
What's Going On With Capricor Therapeutics Stock On Friday?
Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Friday, down by 13%.
benzinga.com
What's Going On With Capricor Therapeutics Stock On Friday?
Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its D
benzinga.com
Capricor Therapeutics Announces FDA's Cellular, Tissue, And Gene Therapies Advisory Committee Intend
Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exos
globenewswire.com
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the
–Advisory Committee meeting scheduled for July 29, 2026– –Company's Biologics License Application on
benzinga.com
Capricor Therapeutics To Present Data From Its Current HOPE-2 Open-Label Extension Trial Of Deramioc
Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exos
globenewswire.com
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in
SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology c